- Reduced inflammation at the site of myocardial infarction and improved heart function demonstrated. Novel therapy to modulate immune response with apoptotic cell-derived nanovesicles. Myocardial ...

Significantly lower risks for MACE, all-cause mortality, incident myocardial infarction, stroke seen for adults 50 years and older with ASCVD.

Conclusions Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline ...

Prior stroke and neurological disability increased long-term mortality after myocardial infarction. Learn how neurological status may guide risk assessment.

The primary end point event (composite of death from CV causes, myocardial infarction, or stroke) occurred in 12.2 and 13.1% in the tirzepatide and dulaglutide groups, respectively. HealthDay News — ...

Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke. (HealthDay News) — Tirzepatide is noninferior to dulaglutide ...